MedPage Today on MSN3d
Investigational ADC Shows Promise in Advanced Endometrial CancerPuxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed ...
A few weeks earlier, it tapped the Chinese biotech for a B7-H4 targeted ADC with potential in gynaecological cancers for $85 million upfront and up to $1.5 billion in milestones. MSD and Daiichi ...
NextCure, Inc. has completed cohort 1 of the Phase 1 trial for its cancer treatment candidate, LNCB74 (B7-H4 ADC), in February 2025 and plans to initiate backfill cohorts later in the year.
H.C. Wainwright says that competitor data demonstrate impressive ORR in endometrial cancer, opening a potential opportunity for NetCure’s ...
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the ...
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025 Cash of approximately $68.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback